Literature DB >> 24757132

Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression.

Joshua F Baker1, Philip G Conaghan, Josef S Smolen, Daniel Aletaha, Justine Shults, Paul Emery, Daniel G Baker, Mikkel Ostergaard.   

Abstract

OBJECTIVE: To develop and validate composite disease activity scores, based on widely available clinical measures, that would demonstrate improved correlation with detection of synovitis on magnetic resonance imaging (MRI) and radiographic progression, in comparison with conventional measures, in patients with rheumatoid arthritis (RA).
METHODS: This study was conducted as a secondary study of 2 RA clinical trials, GO-BEFORE (development cohort) and GO-FORWARD (validation cohort). Generalized estimating equations were used to evaluate independent cross-sectional associations of component variables (from all time points) with concurrent MRI measures of synovitis and bone edema in the development cohort. Based on regression coefficients, modified versions of the Disease Activity Score in 28 joints (M-DAS28), Simplified Disease Activity Index (M-SDAI), and Clinical Disease Activity Index (M-CDAI) were generated for each subject in the validation cohort. The M-DAS28, M-SDAI, and M-CDAI scores were compared to conventional scores of disease activity with regard to associations with MRI measures of synovitis and radiographic progression, assessed using Pearson's and Spearman's correlations, linear/logistic regression, and receiver operating characteristic analysis.
RESULTS: Four variables were independently associated with MRI-detected synovitis and bone edema in the development cohort: C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), swollen joint count in 28 joints (SJC28), and evaluator's global assessment of disease activity using a visual analog scale (EvGA score). Modified disease activity scores were generated using the regression coefficients obtained in the synovitis models for all subjects in the validation cohort; modified scores were calculated as M-DAS28 = 0.49 × ln(CRP) + 0.15 × SJC28 + 0.22 × EvGA + 1 and M-SDAI = CRP + SJC28 + EvGA. Both modified and conventional disease activity scores correlated significantly with MRI measures of synovitis. Modified scores showed superior correlation with synovitis, as compared to conventional scores, at all time points (P < 0.05). Furthermore, the M-DAS28 and M-SDAI had superior test characteristics for prediction of radiographic progression at 52 weeks (both P < 0.05).
CONCLUSION: Modified disease activity scores demonstrated superior correlation with MRI detection of synovitis at all time points, and more accurately predicted radiographic progression in patients with RA in a clinical trial setting.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2014        PMID: 24757132     DOI: 10.1002/art.38304

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  18 in total

1.  Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis.

Authors:  Joshua F Baker; Philip G Conaghan; Paul Emery; Daniel G Baker; Mikkel Østergaard
Journal:  Ann Rheum Dis       Date:  2015-06-19       Impact factor: 19.103

2.  Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis.

Authors:  Jing Cui; Dorothee Diogo; Eli A Stahl; Helena Canhao; Xavier Mariette; Jeffrey D Greenberg; Yukinori Okada; Dimitrios A Pappas; Robert S Fulton; Paul P Tak; Michael T Nurmohamed; Annette Lee; David E Larson; Fina Kurreeman; Tracie L Deluca; Michelle O'Laughlin; Catrina C Fronick; Lucinda L Fulton; Elaine R Mardis; Irene E van der Horst-Bruinsma; Gert-Jan Wolbink; Peter K Gregersen; Joel M Kremer; J Bart A Crusius; Niek de Vries; Tom W J Huizinga; João Eurico Fonseca; Corinne Miceli-Richard; Elizabeth W Karlson; Marieke J H Coenen; Anne Barton; Robert M Plenge; Soumya Raychaudhuri
Journal:  Arthritis Rheumatol       Date:  2017-04       Impact factor: 10.995

3.  Association of Low Muscle Density With Deteriorations in Muscle Strength and Physical Functioning in Rheumatoid Arthritis.

Authors:  Joshua F Baker; Sogol Mostoufi-Moab; Jin Long; Elena Taratuta; Mary B Leonard; Babette Zemel
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-03       Impact factor: 4.794

4.  Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations With Disease Characteristics, Body Composition, and Physical Functioning.

Authors:  Patrick W Gould; Babette S Zemel; Elena G Taratuta; Joshua F Baker
Journal:  J Rheumatol       Date:  2020-11-01       Impact factor: 4.666

5.  The mitochondrial inhibitor oligomycin induces an inflammatory response in the rat knee joint.

Authors:  Carlos Vaamonde-García; Jesús Loureiro; Marta N Valcárcel-Ares; Romina R Riveiro-Naveira; Olalla Ramil-Gómez; Laura Hermida-Carballo; Alberto Centeno; Rosa Meijide-Failde; Francisco J Blanco; María J López-Armada
Journal:  BMC Musculoskelet Disord       Date:  2017-06-12       Impact factor: 2.362

Review 6.  Genetics of rheumatoid arthritis susceptibility, severity, and treatment response.

Authors:  Sebastien Viatte; Anne Barton
Journal:  Semin Immunopathol       Date:  2017-05-29       Impact factor: 9.623

7.  Knee joint synovitis: study of correlations and diagnostic performances of ultrasonography compared with histopathology.

Authors:  Aurélie Najm; Carl Orr; Lorna Gallagher; Monika Biniecka; Emeline Gaigneux; Benoit Le Goff; Ursula Fearon; Douglas J Veale
Journal:  RMD Open       Date:  2018-02-08

8.  Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.

Authors:  Edward C Keystone; Harris A Ahmad; Yusuf Yazici; Martin J Bergman
Journal:  Rheumatology (Oxford)       Date:  2020-08-01       Impact factor: 7.580

9.  Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years.

Authors:  Joshua F Baker; Mikkel Ostergaard; Michael George; Justine Shults; Paul Emery; Daniel G Baker; Philip G Conaghan
Journal:  Ann Rheum Dis       Date:  2014-08-04       Impact factor: 19.103

10.  A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.

Authors:  Stanley Cohen; Alvin F Wells; Jeffrey R Curtis; Rajat Dhar; Theodore Mellors; Lixia Zhang; Johanna B Withers; Alex Jones; Susan D Ghiassian; Mengran Wang; Erin Connolly-Strong; Sarah Rapisardo; Zoran Gatalica; Dimitrios A Pappas; Joel M Kremer; Alif Saleh; Viatcheslav R Akmaev
Journal:  Rheumatol Ther       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.